United States US: Diabetes Prevalence: % of Population Aged 20-79 data was reported at 10.790 % in 2017. United States US: Diabetes Prevalence: % of Population Aged 20-79 data is updated yearly, averaging 10.790 % from Dec 2017 (Median) to 2017, with 1 observations. United States US: Diabetes Prevalence: % of Population Aged 20-79 data remains active status in CEIC and is reported by World Bank. The data is categorized under Global Database’s USA – Table US.World Bank: Health Statistics. Diabetes prevalence refers to the percentage of people ages 20-79 who have type 1 or type 2 diabetes.; ; International Diabetes Federation, Diabetes Atlas.; Weighted average;

Population-based county-level estimates for prevalence of DC were obtained from the Institute for Health Metrics and Evaluation (IHME) for the years 2004-2012 (16). DC prevalence rate was defined as the propor-tion of people within a county who had previously been diagnosed with diabetes (high fasting plasma glu-cose 126 mg/dL, hemoglobin A1c (HbA1c) of 6.5%, or diabetes diagnosis) but do not currently have high fasting plasma glucose or HbA1c for the period 2004-2012. DC prevalence estimates were calculated using a two-stage approach. The first stage used National Health and Nutrition Examination Survey (NHANES) data to predict high fasting plasma glucose (FPG) levels (≥126 mg/dL) and/or HbA1C levels (≥6.5% [48 mmol/mol]) based on self-reported demographic and behavioral characteristics (16). This model was then applied to Behavioral Risk Factor Surveillance System (BRFSS) data to impute high FPG and/or HbA1C status for each BRFSS respondent (16). The second stage used the imputed BRFSS data to fit a series of small area models, which were used to predict county-level prevalence of diabetes-related outcomes, including DC (16). The EQI was constructed for 2006-2010 for all US counties and is composed of five domains (air, water, built, land, and sociodemographic), each composed of variables to represent the environmental quality of that domain. Domain-specific EQIs were developed using principal components analysis (PCA) to reduce these variables within each domain while the overall EQI was constructed from a second PCA from these individual domains (L. C. Messer et al., 2014). To account for differences in environment across rural and urban counties, the overall and domain-specific EQIs were stratified by rural urban continuum codes (RUCCs) (U.S. Department of Agriculture, 2015). Results are reported as prevalence rate differences (PRD) with 95% confidence intervals (CIs) comparing the highest quintile/worst environmental quality to the lowest quintile/best environmental quality expo-sure metrics. PRDs are representative of the entire period of interest, 2004-2012. Due to availability of DC data and covariate data, not all counties were captured, however, the majority, 3134 of 3142 were utilized in the analysis. This dataset is not publicly accessible because: EPA cannot release personally identifiable information regarding living individuals, according to the Privacy Act and the Freedom of Information Act (FOIA). This dataset contains information about human research subjects. Because there is potential to identify individual participants and disclose personal information, either alone or in combination with other datasets, individual level data are not appropriate to post for public access. Restricted access may be granted to authorized persons by contacting the party listed. It can be accessed through the following means: Human health data are not available publicly. EQI data are available at: https://edg.epa.gov/data/Public/ORD/NHEERL/EQI. Format: Data are stored as csv files. This dataset is associated with the following publication: Jagai, J., A. Krajewski, K. Price, D. Lobdell, and R. Sargis. Diabetes control is associated with environmental quality in the USA. Endocrine Connections. BioScientifica Ltd., Bristol, UK, 10(9): 1018-1026, (2021).

This dataset is from UCI machine learning repository: 130 US hospital diabetes dataset However, I did several cleaning and this is the output. How I did the cleaning, you can read more here https://github.com/rischanlab/Cleaning_diabetes_130_US_hospital_dataset

Source

https://archive.ics.uci.edu/ml/datasets/Diabetes+130-US+hospitals+for+years+1999-2008

The data are submitted on behalf of the Center for Clinical and Translational Research, Virginia Commonwealth University, a recipient of NIH CTSA grant UL1 TR00058 and a recipient of the CERNER data. John Clore (jclore '@' vcu.edu), Krzysztof J. Cios (kcios '@' vcu.edu), Jon DeShazo (jpdeshazo '@' vcu.edu), and Beata Strack (strackb '@' vcu.edu). This data is a de-identified abstract of the Health Facts database (Cerner Corporation, Kansas City, MO).

Context

The dataset represents 10 years (1999-2008) of clinical care at 130 US hospitals and integrated delivery networks. It includes over 50 features representing patient and hospital outcomes. Information was extracted from the database for encounters that satisfied the following criteria.

(1) It is an inpatient encounter (a hospital admission).

(2) It is a diabetic encounter, that is, one during which any kind of diabetes was entered to the system as a diagnosis.

(3) The length of stay was at least 1 day and at most 14 days.

(4) Laboratory tests were performed during the encounter.

(5) Medications were administered during the encounter.

The data contains such attributes as patient number, race, gender, age, admission type, time in hospital, medical specialty of admitting physician, number of lab test performed, HbA1c test result, diagnosis, number of medication, diabetic medications, number of outpatient, inpatient, and emergency visits in the year before the hospitalization, etc.

Content

What's inside is more than just rows and columns. Make it easy for others to get started by describing how you acquired the data and what time period it represents, too.

Acknowledgements

We wouldn't be here without the help of others. If you owe any attributions or thanks, include them here along with any citations of past research.

Inspiration

Your data will be in front of the world's largest data science community. What questions do you want to see answered?

The size of the North America Self-monitoring Blood Glucose Market was valued at USD 8.10 Million in 2023 and is projected to reach USD 12.99 Million by 2032, with an expected CAGR of 6.98% during the forecast period. Self-monitoring blood glucose is a relevant tool for patients with diabetes. Its process includes the regular testing of blood sugar to gauge how the body reacts to food, medicine, or physical activity. It helps increase peoples' awareness of their own choices and helps them avoid some complications that may come as a result of diabetes. The North American SMBG market is driven by the increasing incidences of diabetes, especially Type 2. The size and risk profile of the population are critical factors in North America. The region suffers from a rather large population that is susceptible to developing the disease primarily because of obesity, sedentary lifestyles, and aging. With the growth in awareness of diabetes, and with preventive and controlling features forming an important aspect of healthcare systems, the SMBG device and supplies market will continue to grow. The advances in technology, especially the available kinds of continuous glucose monitors, give market expansion way to more convenient and accurate blood sugar tracking. Recent developments include: May 2023: LifeScan announced positive data from a study of real-world evidence supporting its Bluetooth-connected blood glucose meter. Evidence from more than 55,000 people with diabetes demonstrated sustained improvements in readings in range. The analysis focuses on changes over 180 days. LifeScan published results in the peer-reviewed journal Diabetes Therapy. The company’s OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app provide simplicity, accuracy, and trust., January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes is one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.. Key drivers for this market are: Rising Prevalence of Cancer Worldwide, Technological Advancements in Diagnostic Testing; Increasing Demand for Point-of-care Treatment. Potential restraints include: High Cost of Molecular Diagnostic Tests, Lack of Skilled Workforce and Stringent Regulatory Framework. Notable trends are: Blood Glucose Test Strips Held the Largest Market Share in Current Year.

Age-adjusted rate of diabetes deaths by sex, race/ethnicity, age; trends if available. Source: Santa Clara County Public Health Department, VRBIS, 2007-2016. Data as of 05/26/2017; U.S. Census Bureau; 2010 Census, Tables PCT12, PCT12H, PCT12I, PCT12J, PCT12K, PCT12L, PCT12M; generated by Baath M.; using American FactFinder; Accessed June 20, 2017. METADATA:Notes (String): Lists table title, notes and sources.Year (Numeric): Year of data.Category (String): Lists the category representing the data: Santa Clara County is for total population, sex: Male and Female, race/ethnicity: African American, Asian/Pacific Islander, Latino and White (non-Hispanic White only); age categories as follows: 18 to 24, 25 to 34, 35 to 44, 45 to 54, 55 to 64, 65 to 74, 75 to 84, 85+; United States.Rate per 100,000 people (Numeric): Rate of diabetes deaths. Rates for age groups are reported as age-specific rates per 100,000 people. All other rates are age-adjusted rates per 100,000 people.

According to the Juvenile Diabetes Research Foundation (JDRF), almost 1.25 million people in the United States (US) have type 1 diabetes, which makes them dependent on insulin injections. Nationwide, type 2 diabetes rates have nearly doubled in the past 20 years resulting in more than 29 million American adults with diabetes and another 86 million in a pre-diabetic state. The International Diabetes Federation (IDF)has estimated that there will be almost 650 million adult diabetic patients worldwide at the end of the next 20 years (excluding patients over the age of 80). At this time, pancreas transplantation is the only available cure for selected patients, but it is offered only to a small percentage of them due to organ shortage and the risks linked to immunosuppressive regimes. Currently, exogenous insulin therapy is still considered to be the gold standard when managing diabetes, though stem cell biology is recognized as one of the most promising strategies for restoring endocrine pancreatic function. However, many issues remain to be solved, and there are currently no recognized treatments for diabetes based on stem cells. In addition to stem cell research, severalβ-cell substitutive therapies have been explored in the recent era, including the use of acellular extracellular matrix scaffolding as a template for cellular seeding, thus providing an empty template to be repopulated with β-cells. Although this bioengineering approach still has to overcome important hurdles in regard to clinical application (including the origin of insulin producing cells as well as immune-related limitations), it could theoretically provide an inexhaustible source of bio-engineered pancreases

Gross-Profit-Margin Time Series for Tandem Diabetes Care Inc. Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

The North American self-monitoring blood glucose (SMBG) market, valued at $8.10 billion in 2025, is projected to experience robust growth, driven by the increasing prevalence of diabetes and the rising geriatric population. The market's Compound Annual Growth Rate (CAGR) of 6.98% from 2019 to 2025 indicates a consistent upward trend. Key drivers include advancements in SMBG device technology, such as the development of more accurate, user-friendly, and cost-effective glucometers and lancets. Furthermore, increased awareness of diabetes management and the growing adoption of remote patient monitoring contribute significantly to market expansion. While data for individual countries within North America (United States, Canada, and Rest of North America) are not provided, we can infer that the United States likely holds the largest market share given its substantial population and higher prevalence of diabetes compared to Canada. The Rest of North America segment will likely exhibit moderate growth, reflecting the combined market dynamics of smaller countries in the region. Market restraints may include the potential for reimbursement challenges and the emergence of alternative glucose monitoring technologies, such as continuous glucose monitors (CGMs). However, the overall market outlook remains positive, fueled by the persistent need for effective diabetes management. Major players like Abbott, Roche, and LifeScan continue to innovate and compete, further shaping the market landscape. The forecast period (2025-2033) promises continued growth driven by technological advancements and an aging population requiring consistent blood glucose monitoring. The competitive landscape is characterized by established players like Abbott, Roche, and LifeScan, along with other significant contributors like Arkray, Ascensia, and Agamatrix. These companies are continuously striving for innovation to maintain their market share. This involves introducing technologically advanced devices, improving user experience, and developing more comprehensive diabetes management solutions. The increasing demand for accurate, convenient, and affordable SMBG devices, coupled with the growing awareness of diabetes self-management, will drive further market expansion. The incorporation of data analytics and connectivity features in SMBG devices also plays a crucial role in fostering better diabetes management and patient outcomes, thereby bolstering the market's growth trajectory. The focus on improving patient outcomes and reducing healthcare costs will likely shape future market developments, attracting further investments and technological advancements within the sector. Recent developments include: May 2023: LifeScan announced positive data from a study of real-world evidence supporting its Bluetooth-connected blood glucose meter. Evidence from more than 55,000 people with diabetes demonstrated sustained improvements in readings in range. The analysis focuses on changes over 180 days. LifeScan published results in the peer-reviewed journal Diabetes Therapy. The company’s OneTouch Bluetooth-connected blood glucose meter and mobile diabetes app provide simplicity, accuracy, and trust., January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth-Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence from Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes is one of the largest combined blood glucose meter and mobile diabetes app datasets ever published.. Notable trends are: Blood Glucose Test Strips Held the Largest Market Share in Current Year.

Price-To-Tangible-Book-Ratio Time Series for Tandem Diabetes Care Inc. Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

The Latin American diabetes care devices market, valued at approximately $XX million in 2025, is projected to experience robust growth, exhibiting a compound annual growth rate (CAGR) of 5.64% from 2025 to 2033. This expansion is fueled by several key factors. The rising prevalence of diabetes across Brazil, Mexico, and the rest of Latin America, coupled with increasing awareness of effective disease management, is driving demand for both self-monitoring and management devices. Technological advancements, such as the introduction of more user-friendly continuous glucose monitoring (CGM) systems and improved insulin delivery technologies like insulin pumps, are further stimulating market growth. Government initiatives promoting diabetes awareness and affordable access to healthcare are also contributing positively. However, high costs associated with advanced devices, limited healthcare infrastructure in certain regions, and a lack of patient education in some areas pose challenges to market penetration. The market is segmented by device type (self-monitoring blood glucose devices – including glucometers, test strips, and lancets; CGMs – encompassing sensors, receivers, and transmitters; and management devices like insulin pumps, syringes, pens, and jet injectors) and geography (Brazil, Mexico, and the rest of Latin America). Brazil and Mexico are expected to be the largest markets due to their significant populations and relatively higher prevalence of diabetes. The competitive landscape is characterized by the presence of major global players like Abbott, Dexcom, Medtronic, and Roche, alongside several regional players. The future of the Latin American diabetes care devices market appears bright, although further growth hinges on several factors. Addressing affordability concerns through government subsidies and insurance coverage is critical. Furthermore, improving healthcare infrastructure and expanding patient education programs will be crucial to maximizing market potential. Strategic partnerships between manufacturers, healthcare providers, and government bodies can facilitate wider adoption of advanced technologies. Specific focus should be placed on improving access to CGM technology, which offers significant improvements in diabetes management compared to traditional self-monitoring methods. The growing adoption of telehealth and remote monitoring will also contribute to the market's future trajectory. Competitive strategies will likely focus on innovation, product differentiation, and expanding distribution networks to reach diverse patient populations across the region. Recent developments include: January 2023: LifeScan announced that the peer-reviewed Journal of Diabetes Science and Technology published Improved Glycemic Control Using a Bluetooth Connected Blood Glucose Meter and a Mobile Diabetes App: Real-World Evidence From Over 144,000 People With Diabetes, detailing results from a retrospective analysis of real-world data from over 144,000 people with diabetes - one of the largest combined blood glucose meter and mobile diabetes app datasets ever published., October 2022: Becton, Dickinson, and Company and Biocorp announced that they had signed an agreement to use connected technology to track adherence to self-administered drug therapies, like biologics. To support biopharmaceutical companies in their efforts to improve the adherence and outcomes of injectable drugs, the two companies will integrate Biocorp's Injay technology-a solution designed to capture and transmit injection events using Near Field Communication technology to the BD UltraSafe Plus Passive Needle Guard used with pre-fillable syringes.. Notable trends are: The Continuous Glucose Monitoring Segment is expected to witness the highest growth rate over the forecast period.

*(Age-standardised incidence rates per 100,000 individuals per year with 95% confidence intervals. † For cells labeled as NA, 95% CIs could not be estimated as there was only 1 data point).

Property-Plant-and-Equipment-Gross Time Series for Tandem Diabetes Care Inc. Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Sale-Or-Purchase-of-Stock Time Series for Tandem Diabetes Care Inc. Tandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system. It also sells single-use products, including cartridges for storing and delivering insulin, and infusion sets that connect the insulin pump to the user's body. In addition, the company offers Tandem Device Updater used to update the pump software from a personal computer; Tandem Source, a web-based data management platform, which provides a visual way to display diabetes therapy management data from the pumps, integrated CGMs; and Sugarmate, a mobile app used to help people visualize diabetes therapy data. It has collaboration agreement with the University of Virginia Center for Diabetes Technology for research and development of fully automated closed-loop insulin delivery systems. The company was formerly known as Phluid Inc. and changed its name to Tandem Diabetes Care, Inc. in January 2008. Tandem Diabetes Care, Inc. was incorporated in 2006 and is headquartered in San Diego, California.

Net-Income-Including-Non-Controlling-Interests Time Series for Senseonics Holdings Inc. Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.

Long-Term-Investments Time Series for Senseonics Holdings Inc. Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.

The share of the population with overweight in the United States was forecast to continuously increase between 2024 and 2029 by in total 1.6 percentage points. After the fifteenth consecutive increasing year, the overweight population share is estimated to reach 77.43 percent and therefore a new peak in 2029. Notably, the share of the population with overweight of was continuously increasing over the past years.Overweight is defined as a body mass index (BMI) of more than 25.The shown data are an excerpt of Statista's Key Market Indicators (KMI). The KMI are a collection of primary and secondary indicators on the macro-economic, demographic and technological environment in up to 150 countries and regions worldwide. All indicators are sourced from international and national statistical offices, trade associations and the trade press and they are processed to generate comparable data sets (see supplementary notes under details for more information).Find more key insights for the share of the population with overweight in countries like Canada and Mexico.

Aim: Non-alcoholic fatty liver disease (NAFLD) exhibits a racial disparity. We examined the prevalence and the association between race, gender, and NAFLD among prediabetes and diabetes populations among adults in the United States.Methods: We analyzed data for 3,190 individuals ≥18 years old from the National Health and Nutrition Examination Survey (NHANES) 2017–2018. NAFLD was diagnosed by FibroScan® using controlled attenuation parameter (CAP) values: S0 (none) < 238, S1 (mild) = 238–259, S2 (moderate) = 260–290, S3 (severe) > 290. Data were analyzed using Chi-square test and multinomial logistic regression, adjusting for confounding variables and considering the design and sample weights.Results: Of the 3,190 subjects, the prevalence of NAFLD was 82.6%, 56.4%, and 30.5% (p < 0.0001) among diabetes, prediabetes and normoglycemia populations respectively. Mexican American males with prediabetes or diabetes had the highest prevalence of severe NAFLD relative to other racial/ethnic groups (p < 0.05). In the adjusted model, among the total, prediabetes, and diabetes populations, a one unit increase in HbA1c was associated with higher odds of severe NAFLD [adjusted odds ratio (AOR) = 1.8, 95% confidence level (CI) = 1.4–2.3, p < 0.0001; AOR = 2.2, 95% CI = 1.1–4.4, p = 0.033; and AOR = 1.5, 95% CI = 1.1–1.9, p = 0.003 respectively].Conclusion: We found that prediabetes and diabetes populations had a high prevalence and higher odds of NAFLD relative to the normoglycemic population and HbA1c is an independent predictor of NAFLD severity in prediabetes and diabetes populations. Healthcare providers should screen prediabetes and diabetes populations for early detection of NAFLD and initiate treatments including lifestyle modification to prevent the progression to non-alcoholic steatohepatitis or liver cancer.

Diluted-Average-Shares Time Series for Senseonics Holdings Inc. Senseonics Holdings, Inc., a commercial-stage medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, Eversense E3, and Eversense 365, which are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and an app for real-time diabetes monitoring and management. It serves healthcare providers and patients through a network of distributors and strategic fulfillment partners. The company was founded in 1996 and is headquartered in Germantown, Maryland.

Data for cities, communities, and City of Los Angeles Council Districts were generated using a small area estimation method which combined the survey data with population benchmark data (2022 population estimates for Los Angeles County) and neighborhood characteristics data (e.g., U.S. Census Bureau, 2017-2021 American Community Survey 5-Year Estimates). The current Physical Activity Guidelines for Americans is issued by the US Department of Health and Human Services. To meet physical activity guidelines, adults must meet aerobic physical activity guidelines (vigorous activity for at least 75 minutes a week, or moderate activity for at least 150 minutes a week, or a combination of vigorous and moderate activity for at least 150 minutes a week) and muscle-strengthening physical activity guidelines (exercise all major muscle groups on 2 or more days a week).Physical inactivity contributes to our current obesity epidemic and is a major risk factor for heart disease, diabetes, cancer, and many other chronic health conditions. It can be difficult for people to be physically active if their communities do not have available and safe places for recreation.For more information about the Community Health Profiles Data Initiative, please see the initiative homepage.